Latest Myriad Genetics Inc. Stories
Agreement ensures continuing broad patient access to Quest's BRCAvantage(TM) services for evaluating genetic risk of developing breast, ovarian and other cancers MADISON, N.J., Feb.
Petitions aim to nullify cancer gene patents owned, co-owned, or licensed by Myriad Genetics, Inc. WASHINGTON, Aug.
Plaintiffs, including the American Civil Liberties Union, Association for Molecular Pathology, and American Society for Clinical Pathology, win long-fought case against Myriad Genetics, Association
A Salt Lake City, Utah-based genetics firm has lost a battle in court to keep a patent on naturally-occurring human genes.
SALT LAKE CITY, Sept. 14 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that it has launched a hereditary breast and ovarian cancer Public Awareness Campaign in five Midwest states, including Illinois, Indiana, Kentucky, Missouri and Ohio.
- To fire mitraille at.